Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases.
The last earnings update was 109 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Axovant Gene Therapies. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
Axovant Gene Therapies's
is considered below, and whether this is a fair price.
Price based on past earnings
Axovant Gene Therapies's earnings available for a low price, and how does
this compare to other companies in the same industry?
Axovant Gene Therapies's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Axovant Gene Therapies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Axovant Gene Therapies's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
Axovant Gene Therapies
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Axovant Gene Therapies's finances.
The net worth of a company is the difference between its assets and liabilities.
Axovant Gene Therapies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Axovant Gene Therapies's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Axovant Gene Therapies's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 1.9x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Pavan Cheruvu, M.D., has been Chief Executive Officer of Axovant Sciences Ltd. since February 12, 2018 and as its Director since September 26, 2018. Dr. Cheruvu provides medical oversight for Hale’s work in cardiovascular health. He serves as an General Cardiology fellow at UCSF’s Cardiac Catheterization Laboratory. Prior to joining Axovant, Dr. Cheruvu held roles of increasing responsibility at Roivant and supporting Axovant since 2015 and was appointed to the Roivant executive leadership team in 2017. A board-certified physician, Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training in a clinical fellowship in cardiovascular medicine at the University of California, San Francisco. Prior to his medical training, Dr. Cheruvu was a management consultant at McKinsey & Company from June 2008 through June 2011, where he focused on biopharmaceutical strategy. He earned his B.S.E. in biomedical engineering, B.S.E. in electrical engineering, and A.B. in chemistry from Duke University summa cum laude, his M.Sc. in computer science from Oxford University where he was a Rhodes Scholar, and his M.D. from Harvard Medical School. Prior to joining Axovant, Dr. Cheruvu worked at RSI since October 2015, and was appointed to RSI’s executive leadership team in September 2017.
Insufficient data for Pavan to compare compensation growth.
Pavan's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
Axovant Gene Therapies
management team in years:
The average tenure for the Axovant Gene Therapies management team is less than 2 years, this suggests a new team.
CEO & Director
Principal Financial & Accounting Officer
Scientific Advisor of Group
Chief Technology Officer
Head of Investor Relations
Head of Global Transactions & Risk Management
Chief Medical Officer
Chief Business Officer
Executive Vice President of Research & Development
Board of Directors Tenure
Average tenure and age of the
Axovant Gene Therapies
board of directors in years:
The average tenure for the Axovant Gene Therapies board of directors is less than 3 years, this suggests a new board.
Board of Directors
CEO & Director
Lead Independent Director
Senior Scientific Advisor & Chairman of the Scientific Advisory Board
Does The Axovant Gene Therapies Ltd. (NASDAQ:AXGT) Share Price Fall With The Market?
(NASDAQ:AXGT), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Because it takes less capital to move the share price of a small company like this, when a stock this size is actively traded it is quite often more sensitive to market volatility than similar large companies. … What this means for you: Since Axovant Gene Therapies tends to moves up when the market is going up, and down when it's going down, potential investors may wish to reflect on the overall market, when considering the stock.
Investors Who Bought Axovant Gene Therapies (NASDAQ:AXGT) Shares Three Years Ago Are Now Down 92%
So take a moment to sympathize with the long term shareholders of Axovant Gene Therapies Ltd. … It seems likely some shareholders believe that Axovant Gene Therapies has the funding to invent a new product before too long. … Axovant Gene Therapies has already given some investors a taste of the bitter losses that high risk investing can cause.
Have Insiders Been Buying Axovant Sciences Ltd. (NASDAQ:AXGT) Shares?
We often see insiders buying up shares in companies that perform well over the long term. … Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. … It's very possible they regret the purchase, but it's more likely they are bullish about the company.
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company’s current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson’s disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in New York, New York. Axovant Gene Therapies Ltd. operates as a subsidiary of Roivant Sciences Ltd.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.